title: Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine.
abstract: Designing an HIV-1 envelope glycoprotein (Env) that can induce broadly neutralizing antibodies in humans remains one of the great challenges in biomedical research. Monomeric gp120 has repeatedly failed to induce cross-neutralizing antibodies in clinical trials. Spearman et al. vaccinated uninfected volunteers with a trimeric gp140 protein. They found that the vaccine was safe and induced neutralizing antibody responses against the homologous virus, but not cross-neutralizing responses. The results reinforce the notion that our Env vaccine design needs to improve.
authors.affiliation: Laboratory of Experimental Virology, Department of Medical Microbiology, Academic Medical Center of the University of Amsterdam, Amsterdam The Netherlands. r.w.sanders@amc.uva.nl
authors.forename: Rogier W
authors.initials: RW
authors.lastname: Sanders